ArticleCureus2025
Pharmacological Privilege: How Glucagon-Like Peptide-1 (GLP-1) Medications are Widening Health Inequalities.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity remains a growing cause of morbidity and mortality, disproportionately affecting socioeconomically disadvantaged groups. Glucagon-like peptide-1 (GLP-1) agonist medications promote significant weight loss, giving hope to public healthcare systems increasingly stretched by obesity-related cardiometabolic disorders. Despite increased use of GLP-1 agonists for this indication, the need for these medications greatly outstrips supply due to financial and logistical constraints. The high cost of these medications is currently prohibitive to widespread rollout, yet they remain accessible privately for those able to afford them. This disparity reflects Julian Tudor Hart's inverse care law, in which access to effective healthcare inversely correlates with need. Achieving fair and sustainable integration of GLP-1 therapies will require evidence-informed policies that ensure treatment based on need rather than means. Equitable global access, supported by investment in preventive, population-level strategies, is essential to promote health and avoid deepening worldwide health inequalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.